JNJ241213C148000
- 0.01
- 0.000.00%
Johnson & Johnson Newsroom
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
Stock Of The Day: Will Johnson & Johnson Take The Market Lower?
CES Tech Conference Week Starts with Nvidia and Chips Climbing | Live Stock
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Best Income Ideas for 2025: Stocks, Bonds, and Everything in Between
Santa Claus Came Without Rallying the Troops | Live Stock
Dividend Roundup: Johnson & Johnson, JPMorgan, Oracle, Mastercard, and More
Johnson & Johnson To Go Ex-Dividend On February 18th, 2025 With 1.24 USD Dividend Per Share
U.S. Companies With Potential Pension Risk Transfer Restructuring Opportunities
5 Low-Leverage Stocks Worth Adding to Your Portfolio in 2025
Smart Money Is Betting Big In JNJ Options
Johnson & Johnson Declares $1.24 Quarterly Dividend; 3.4% Yield
Press Release: Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
Express News | Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ.US) has applied for the market launch of its innovative compound drug "Mexitentan Tadalafil Tablets" in China for the treatment of pulmonary arterial hypertension.
The CDE website shows that Johnson & Johnson (JNJ.US) has submitted an application for the innovative compound drug "Maqitengtan Tadalafil Tablets" to be marketed domestically for the treatment of pulmonary arterial hypertension (PAH).
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025